Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleogel-S10 in Japanese patients with junctional or dystrophic epidermolysis bullosa
NCT06917690Phase 3Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of birch triterpenes in junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB), sponsored by Chiesi Farmaceutici S.p.A.. Started Apr 2025; status: recruiting.
02
Drugs
birch triterpenes
03
Conditions
junctional epidermolysis bullosa (JEB)dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT06917690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917690.